Home » Stocks » GNMK

GenMark Diagnostics, Inc. (GNMK)

Apr 22, 2021 - GNMK was delisted (reason: acquired by Roche)
Stock Price: $24.04 USD 0.00 (0.00%)
Updated Apr 21, 2021 4:00 PM EDT
Market Cap 1.77B
Revenue (ttm) 171.55M
Net Income (ttm) -18.64M
Shares Out 73.60M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jul 25, 2021
Last Price $24.04
Previous Close $24.04
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 24.03 - 24.06
Day's Volume -
52-Week Range 8.47 - 24.25

News

Hide News

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...

Other stocks mentioned: ADPT, BRN, RHHBY, VIVO
3 months ago - GuruFocus

NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX)  concerning potent...

Other stocks mentioned: CADE, LMNX, NUAN
3 months ago - PRNewsWire

Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of pro...

Other stocks mentioned: LMNX, QDEL, RHHBY
3 months ago - GuruFocus

GenMark Diagnostics (GNMK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 months ago - Zacks Investment Research

NEW YORK, March 19, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class ...

4 months ago - PRNewsWire

NEW YORK and SAN DIEGO, March 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics ("GenMark") (NASDAQ: GNMK) regarding possible brea...

4 months ago - PRNewsWire

GenMark Diagnostics (GNMK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...

4 months ago - Zacks Investment Research

A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.

Other stocks mentioned: RHHBY
4 months ago - The Motley Fool

WILMINGTON, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiducia...

4 months ago - GlobeNewsWire

GenMark Diagnostics Inc (NASDAQ:GNMK) stock is surging today, up 29.1% to trade at $23.88 at last check, after news of its buyout.

4 months ago - Schaeffers Research

NEW YORK, March 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GenMark Diagnostics, Inc. ("GenMark" o...

4 months ago - PRNewsWire

NEW YORK and SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics (“GenMark”) (NASDAQ: GNMK) regarding possible ...

4 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Un...

4 months ago - Business Wire

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

Other stocks mentioned: RHHBY
4 months ago - Zacks Investment Research

Roche Holding AG (SWX: RO) said on Monday that it will buy GenMark Diagnostics (NASDAQ: GNMK) for £1.29 billion. The all-cash deal translates to £17.25 per share.

Other stocks mentioned: RHHBY
4 months ago - Invezz

Roche Diagnostics CEO: GenMark deal will further expand global reach

YouTube video

Roche Diagnostics CEO Thomas Schinecker discusses the Swiss pharma company's acquisition of GenMark Diagnostics for $1.8 billion.

Other stocks mentioned: RHHBY
4 months ago - CNBC International TV

Swiss drug giant Roche Holding AG (OTC: RHHBY) announced a big-ticket acquisition that would boost its presence in the diagnostics market, setting the tempo for a merger Monday. What Happened: Roche sai...

Other stocks mentioned: RHHBY
4 months ago - Benzinga

Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.

Other stocks mentioned: RHHBY
4 months ago - Reuters

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its eP...

5 months ago - GlobeNewsWire

GenMark Diagnostics (GNMK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems...

5 months ago - GlobeNewsWire

Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients Major teaching hospital in Grenoble, France demonstrates t...

5 months ago - GlobeNewsWire

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close...

5 months ago - GlobeNewsWire

Bloomberg stated that GenMark Diagnostics Inc (NASDAQ: GNMK) is reportedly exploring a sale and has been contacted by multiple potential buyers. The company is said to have engaged a financial advisor t...

5 months ago - Benzinga

The company could be a potential acquisition target.

5 months ago - The Motley Fool

Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Growth In 2021...

Other stocks mentioned: AMRS, CLNE, HIMX, INO, STKL, UMC
5 months ago - InvestorPlace

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary ...

6 months ago - GlobeNewsWire

These winners are positioned for gains even after COVID.

Other stocks mentioned: FLGT, NTRA, NVS, PFE
6 months ago - The Motley Fool

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems...

6 months ago - GlobeNewsWire

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems...

8 months ago - GlobeNewsWire

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CARLSBAD, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial r...

8 months ago - GlobeNewsWire

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, ...

9 months ago - GlobeNewsWire

GenMark Diagnostics just received emergency approval for its coronavirus test panel. GNMK stock is soaring as a result.

9 months ago - InvestorPlace

Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory illnesses...

9 months ago - GlobeNewsWire

Tests that can screen for the flu, the coronavirus and other pathogens could be crucial in combating Covid-19 and influenza this winter, public health specialists say.

9 months ago - CNBC

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth

9 months ago - GlobeNewsWire

Investors need to pay close attention to GenMark Diagnostics (GNMK) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season

10 months ago - GlobeNewsWire

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.

Other stocks mentioned: CODX, QDEL
10 months ago - Benzinga

Blame it on Abbott.

Other stocks mentioned: CODX, LMNX, OPK
10 months ago - The Motley Fool

Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity

11 months ago - GlobeNewsWire

Investing For The Long Run: Navigating A Bifurcated Market

Other stocks mentioned: ABBV, EMN, ENB, EPD, MO, MSFT, PRU ...
11 months ago - Seeking Alpha

Most medical diagnostic and research companies tend not to be involved in the COVID-19 virus vaccine race, but entries who are need tools to speed their pace.

11 months ago - Seeking Alpha

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of GenMark Diagnostics (NASDAQ:GNMK) moved lower by 6.81% in after-market trading after the company reported Q2 results.

11 months ago - Benzinga

CARLSBAD, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial...

11 months ago - GlobeNewsWire

CARLSBAD, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the c...

11 months ago - GlobeNewsWire

Is (GNMK) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

About GNMK

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative pa... [Read more...]

Industry
Medical Devices
IPO Date
May 28, 2010
Stock Exchange
NASDAQ
Ticker Symbol
GNMK
Full Company Profile

Financial Performance

In 2020, GNMK's revenue was $171.55 million, an increase of 94.90% compared to the previous year's $88.02 million. Losses were -$18.64 million, -60.63% less than in 2019.

Financial Statements